Recent events
Recent events tied to this brand in public sources.
Back to profile3 entries
2021
ReShape Lifesciences reports 2020 financial results
ReShape Lifesciences reported its fourth-quarter and full-year 2020 financial and operational results, including full-year revenue of $11.3 million and a non-GAAP adjusted EBITDA loss of $9.1 million.
2019
ReShape Lifesciences partners with Sequence Health to market LAP-BAND
ReShape Lifesciences announced that it signed a marketing agreement with Sequence Health to promote LAP-BAND procedures in the United States. Sequence Health will run a targeted direct-to-patient digital marketing campaign.
2019
ReShape Lifesciences appoints Thomas Stankovich CFO
ReShape Lifesciences appointed Thomas Stankovich as chief financial officer, effective immediately.